microdose.glp 1 Exploring Microdosing GLP-1 Medications: Benefits Beyond Weight Loss Noom Launches GLP-1 Microdosing for

The patient started treatment with a Glucagon-like peptide 1 receptor agonist and lost 24% of her body weight over the next 13 months

Source: Segal SHAPE, Segals data warehouse, 2018 to 2022 Even though many plans currently do not cover weight-loss medications, these plans are still seeing the effect that the GLP-1 medication class is having on their diabetic plan spend

Based on the trends in CDERs FY 2025 activity, there are a few practical steps regulatory and quality leaders should consider here: Tighten supply chain and vendor controls

Edwards CM, Stanley SA, Davis R, et al

In recent years, medicines in this class, including semaglutide which is the active ingredient in both Ozempic and Wegovy have attracted intense scientific and public interest because of their effects on body weight and cardiometabolic risk